Posted on: Thu 25-06-2026

As Africa confronts one of its most persistent yet underfunded public health challenges, renowned haematologist and global health advocate Dr. Maureen Okam Achebe is helping shape a new continental vision for sickle cell disease care—one that could save hundreds of thousands of lives and transform health outcomes for future generations.

A graduate of the University of Port Harcourt and a distinguished physician-scientist at Harvard Medical School, Dr. Achebe has emerged as one of the leading voices advancing equitable access to sickle cell disease diagnosis, treatment, and long-term care across Africa.

Currently serving as Clinical Director of Hematology Services at Brigham and Women's Hospital and Dana-Farber Cancer Institute, as well as Associate Professor of Medicine and Global Health Equity at Harvard Medical School, her work spans clinical care, research, policy development, and international health systems strengthening.

 

A Turning Point for Sickle Cell Disease in Africa

Dr. Achebe described the recent launch of the Africa Centres for Disease Control and Prevention (Africa CDC) Continental Framework for Sickle Cell Disease and Other Inherited Blood Disorders as a historic milestone in the fight against one of Africa's most significant non-communicable genetic health conditions.

According to her, the initiative represents a coordinated and strategic response to a disease that has affected African populations for generations but has often received insufficient policy attention and investment.

The continental plan, developed through a technical working group established in 2025, seeks to provide African countries with a practical roadmap for improving diagnosis, treatment, surveillance, and long-term disease management.

Health experts believe the framework could become one of the most important public health interventions for inherited blood disorders on the continent.

 

The Promise of Newborn Screening

One of the most transformative aspects of current sickle cell interventions is newborn screening.

Through the Consortium on Newborn Screening in Africa (CONSA), supported by the American Society of Hematology and multiple international partners, nearly **175,000 newborns** have already been screened across participating African countries.

Dr. Achebe noted that the programme has demonstrated that large-scale newborn screening is both feasible and sustainable within African health systems.

More importantly, it has shown that infants diagnosed early can be linked to care and receive life-saving interventions before severe complications develop.

The initiative has also strengthened laboratory capacity, improved clinical training, enhanced data collection systems, and promoted cross-country collaboration in sickle cell disease management.

 

Saving Lives Through Early Detection

The burden of sickle cell disease remains particularly severe in sub-Saharan Africa, where an estimated 300,000 babies are born annually with the condition.

Without early diagnosis and treatment, many affected children die before reaching their fifth birthday.

Dr. Achebe emphasized that widespread newborn screening combined with early intervention has the potential to prevent more than **95 percent of under-five deaths** associated with sickle cell disease, replicating the remarkable outcomes achieved in many high-income countries.

For public health experts, these figures highlight the enormous opportunity to reduce childhood mortality through relatively cost-effective and evidence-based interventions.

 

Funding Remains a Critical Challenge

Despite growing progress, Dr. Achebe acknowledged that sickle cell disease continues to receive insufficient financial support relative to its burden.

She called for stronger commitment from African governments, health ministries, and development partners to prioritise sickle cell disease within national health strategies and budget allocations.

According to her, sustainable progress will depend on integrating screening and treatment programmes into existing healthcare systems rather than relying solely on externally funded initiatives.

Health economists have long argued that investments in early diagnosis and disease management generate significant long-term social and economic returns by reducing mortality, preventing disability, and improving workforce productivity.

 

Building Models of Excellence Across Africa

While challenges remain, several African countries are already demonstrating innovative approaches to sickle cell disease care.

Dr. Achebe noted that countries with higher disease burdens have increasingly developed targeted strategies tailored to their unique epidemiological realities.

These approaches range from newborn screening and specialised clinics to community-based care models and national awareness campaigns.

Although no single model fits every country, the collective experience provides valuable lessons for scaling interventions across the continent.

 

Measuring Success in the Next Five Years

Looking ahead, Dr. Achebe believes success should be measured not only by policy declarations but by tangible improvements in diagnosis, treatment access, and survival outcomes.

Key indicators include the adoption of national newborn screening programmes, increased enrolment of diagnosed children into specialised care pathways, improved access to essential treatments, strengthened healthcare workforce capacity, and reductions in childhood mortality associated with sickle cell disease.

Ultimately, she envisions a future in which every child born with sickle cell disease in Africa is identified early, linked to appropriate care, and given the opportunity to live a healthy and productive life.

 

A Vision for Health Equity

Beyond her clinical and research contributions, Dr. Achebe's work represents a broader commitment to health equity and healthcare justice.

Her leadership demonstrates how African expertise, global partnerships, scientific innovation, and health system strengthening can converge to address longstanding health challenges affecting millions across the continent.

As Africa advances toward implementing a continent-wide sickle cell disease strategy, healthcare professionals, policymakers, researchers, and patient advocates increasingly view newborn screening and early intervention as essential tools for changing the trajectory of one of the continent's most significant inherited diseases.

For the millions of families affected by sickle cell disease, the message is increasingly clear: early diagnosis, coordinated care, and sustained investment have the power to transform survival into thriving and disease management into health equity.

---

---